4D Molecular Therapeutics FDMT Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: 4D Molecular Therapeutics’s 10-Q, filed November 10, 2025, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's free cash flow margin?
- 4D Molecular Therapeutics (FDMT) reported free cash flow margin of -154,209.2% in Q3 2025.
- How has 4D Molecular Therapeutics's free cash flow margin changed year-over-year?
- 4D Molecular Therapeutics's free cash flow margin increased by 52.5% year-over-year, from -324,327.8% to -154,209.2%.
- What is the long-term trend for 4D Molecular Therapeutics's free cash flow margin?
- Over 4 years (2020 to 2024), 4D Molecular Therapeutics's free cash flow margin has grown at a 469.4% compound annual growth rate (CAGR), from -355.8% to -373,975.7%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.